Wyeth Hemophilia History

A History of Recombinant Experience

We are Wyeth. We seek to improve the future for the hemophilia community, from discovering and developing
recombinant coagulation factors to partnering with other organizations to improve the treatment of hemophilia.

In the 1980s, visionary scientists founded Genetics Institute (later acquired by Wyeth) to assemble a first-class team of scientists and business professionals to develop and commercialize protein-based therapeutic products through genetic engineering.

Today, Wyeth is the only company to offer both a recombinant factor VIII and a recombinant factor IX product.

Milestones for Wyeth Hemophilia Therapy

	In 1992, the first recombinant antihemophilic factor (rAHF) for the treatment of hemophilia A, developed by Genetics Institute, was brought to market.
	In 1997, BeneFIX, the first and only recombinant factor IX for hemophilia B, was introduced.
	In 2002, ReFacto, a recombinant factor VIII with an albumin-free final formulation,* was introduced.
	In 2008, XYNTHA, a recombinant factor VIII product that is completely albumin-free† and uses a purification process free of added human or animal materials, was introduced.

 

*The Chinese hamster ovary cell line used to produce ReFacto is grown in culture medium that contains human serum albumin. Following purification, the albumin concentration is below the detection limit of the assay.

^†The chemically defined cell culture medium in which the Chinese hamster ovary (CHO) cells are grown contains artificial insulin, but does not contain any materials derived from human or animal sources.